Cost-effectiveness analyses of augmented cognitive behavioral therapy for pharmacotherapy-resistant depression at secondary mental health care settings.

Mitsuhiro SadoAkihiro KorekiAkira NinomiyaChika KurataDai MitsudaYasunori SatoToshiaki KikuchiDaisuke FujisawaYutaka OnoMasaru Mimura Atsuo Nakagawa

Published in: Psychiatry and clinical neurosciences (2021)

Augmented CBT for pharmacotherapy-resistant depression is not cost-effective for all samples including mild depression. In contrast, it appeared to be cost-effective for the patients currently manifesting moderate/severe symptoms under secondary mental health care.

Keyphrases

sleep quality
depressive symptoms
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
smoking cessation
peritoneal dialysis
early onset
prognostic factors
computed tomography
physical activity
obsessive compulsive disorder
deep brain stimulation